HalioDx is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
As an immunologist, I founded HalioDx in 2014 with my former partners at Ipsogen and Jérôme Galon, a world specialist in cancer immunology. HalioDx implements a radically new approach to cancer diagnosis based on the analysis of the immune response: by precisely measuring the anti-tumour immune response of patients, we enable doctors to determine the severity of the disease, regardless of the cancer stage or molecular profile. Using this measurement, they should also be able to predict the response to treatment of their patients, including immunotherapies, which are at the core of the MI project.
To drive these innovations, HalioDx relies on a team of 80 employees that has already established its expertise in cancer diagnosis and has enabled the buyout of the company Ipsogen by the Qiagen group in 2011, after a successful industrial career and stock market performance. Again independent, HalioDx is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.#industrie
“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the g9d2 T cells and a novel superfamily of immunomodulators, butyrophilins”
For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.
Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells
AMU, IPC, CRCM